Search Contract Opportunities

EBOLA Vaccine   3

ID: 17-100-SOL-00013 • Type: Solicitation
SAM = Too Late

Find opportunities months or years earlier with HigherGov forecasts

Schedule Demo Start Trial

Description

UPDATE JUNE 29, 2017: AMENDMENT #4 IS NOW POSTED. THE PROPOSAL SUBMISSION DUE DATE HAS BEEN EXTENDED TO JULY 5, 2017. PLEASE SEE ATTACHMENT.
UPDATE JUNE 13, 2017: AMENDMENT #3 IS NOW POSTED. PLEASE SEE ATTACHMENT FOR AN UPDATED MAILING ADDRESS FOR PROPOSAL SUBMISSION.UPDATE June 1, 2017: AMENDMENT #2 AND ANSWERS TO QUESTIONS ARE NOW POSTED. THE PROPOSAL SUBMISSION DUE DATE HAS BEEN EXTENDED TO JUNE 30, 2017. PLEASE SEE ATTACHMENT. UPDATE May 16, 2017: AMENDMENT #1 IS NOW POSTED. THE QUESTION SUBMISSION DUE DATE HAS BEEN EXTENDED TO MAY 30, 2017. THE PROPOSAL DUE DATE OF JUNE 23, 2017 HAS NOT CHANGED. PLEASE SEE ATTACHMENT.
UPDATE May 8, 2017: THIS IS A SOLICITATION NOTICE. PLEASE SEE ATTACHMENT. April 18, 2017:THIS IS A PRE-SOLICITATION NOTICE. PLEASE SEE ATTACHMENT.
Background
The Department of Health & Human Services, Office of the Secretary, Assistant Secretary for Preparedness & Response is issuing a pre-solicitation notice for the development of an Ebola vaccine. The notice emphasizes the urgent need for medical countermeasures (MCM) against Ebola virus and highlights the high-priority threat of Ebola virus as determined by the Secretary of Homeland Security. The goal of the contract is to develop a vaccine suitable for protection against Ebola virus, specifically Zaire Ebolavirus, for use in the U.S. civilian population in individuals with an elevated risk of exposure to Ebola.

Work Details
The work involves the development of a vaccine that can be safely and effectively used for individuals with an elevated risk of exposure to Ebola, specifically Zaire Ebolavirus. Proposals submitted to any future solicitations should have evidence of an active IND (with the Food and Drug Administration) with ongoing or completed Phase 2 or 3 clinical studies and provide evidence of non-clinical efficacy in a nonhuman primate model of Ebola infection.
Show All

Overview

Agency
HHS Immediate Office of the Secretary (IOS) [HHS]
Response Deadline
July 5, 2017, 1:00 p.m. EDT Past Due
Posted
June 29, 2017, 12:11 p.m. EDT
Set Aside
None
NAICS
541711 - Research And Development In Biotechnology
PSC
A - Research And Development
Place of Performance
Not Provided
Source
SAM
Est. Level of Competition
Average
Signs of Shaping
The solicitation is open for 6 days, below average for the HHS Immediate Office of the Secretary.
On 6/29/17 HHS Immediate Office of the Secretary issued Solicitation 17-100-SOL-00013 for EBOLA Vaccine due 7/5/17. The opportunity was issued full & open with NAICS 541711 and PSC A.
Primary Contact
Name
Christopher T. Scott   Profile
Email
christopher.scott@hhs.gov
Phone
None

Documents

Posted documents for Solicitation 17-100-SOL-00013

Question & Answer

Opportunity Lifecycle

Procurement notices related to Solicitation 17-100-SOL-00013

Award Notifications

Agency published notification of awards for Solicitation 17-100-SOL-00013

Contract Awards

Prime contracts awarded through Solicitation 17-100-SOL-00013

Incumbent or Similar Awards

Potential Bidders and Partners

Awardees that have won contracts similar to Solicitation 17-100-SOL-00013

Similar Active Opportunities

Open contract opportunities similar to Solicitation 17-100-SOL-00013

Additional Details

Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > IMMED OFFICE OF THE SECRETARY OF HEALTH AND HUMAN SERVICES > Acquisitions Management, Contracts, & Grants (AMCG)
Source Organization Code
b67f10c42dff7fb763de08f7751530e8
Last Updated
June 29, 2017
Last Updated By
PI33_DR_IAE_51681
Archive Date
June 29, 2017